Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

October 26-28, 2017

New York, New York
Sheraton New York

Scientific Agenda

In addition to the General Session at this year's Lymphoma & Myeloma, we are excited to offer a concurrent track specifically designed to meet the educational needs of nurses and advanced practitioners who treat hematologic malignancies.

 

GENERAL SESSION


Thursday, October 26, 2017

8:00 am

Welcome and introduction
Morton Coleman, MD

MYELOMA SESSION

8:05 am

Introduction to Myeloma Session
Ruben Niesvizky, MD

Session I: Precision Medicine in Myeloma

Moderator: Moderator invited

8:10 am

Sequencing the genome in myeloma: Pitfalls and opportunities in the Clinic
Speaker invited

8:30 am

Harnessing the cell cycle: Applying the state of the art
Speaker invited

8:50 am

How many myelomas are there? Do we treat them differently?
Speaker invited

9:10 am

DEBATE: MRD, Ready for Primetime?

Pro
C. Ola Landgren, MD, PhD

Con
Paul G. Richardson, MD

9:40 am

Break

Session II: Immuno Oncology in Myeloma

Moderator: Moderator invited

10:00 am

Role of vaccine therapy in multiple myeloma
Speaker invited

10:20 am

Anti CD38 and anti SLAMF7 Therapeutics: Are they ready to go upfront?
Joseph Mikhael MD, MEd, FRCPC, FACP

10:40 am

The Future in multiple myeloma: BiTES, CAR-T, and checkpoint inhibitors
Adam D. Cohen, MD

11:00 am

Panel discussion

Session III: Treatment I

Moderator: Ruben Niesvizky, MD

11:15 am

Precursor disorders and smoldering myeloma: Are they curable?
Adriana Rossi, MD

11:35 am

DEBATE: Which initial therapy for younger fit patients is best?

KRD and VRD
Ajai Chari, MD

CyBord and BiRd
Speaker invited

12:05 pm

Panel discussion

12:20 pm

Luncheon

Session IV: Treatment II

Moderator: Adriana Rossi, MD

1:50 pm

DEBATE: One size fits all? Should everyone eligible get upfront autologous stem cell transplant?

Pro
Phillipe Moureau, MD

Con
James Berenson, MD

2:20 pm

DEBATE: In the relapsed patient, what would be the ideal treatment?

IMid plus protease inhibitor?
Speaker invited

IMid plus monoclonal antibody?
Tomer Mark, MD, MSc

2:50 pm

Panel discussion

Session V: Treatment III

Moderator: Cara Rosenbaum, MD

3:10 pm

Is there a role for allogeneic transplant in any young fit myeloma patient?
Speaker invited

3:30 pm

p53: Is there anything we can do therapeutically?
Speaker invited

3:50 pm

New horizons in the treatment of relapsed and refractory myeloma
Kenneth Anderson, MD

4:10 pm

Break

Session VI: Treatment IV

Moderators: Morton Coleman, MD and Ruben Niesvizky, MD

4:30 pm

The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: Joseph Michaeli Award for Contributions to Myeloma Research
Presenter: Phillipe Moureau, MD

4:40 pm

Keynote Lecture: Current Approach to the Treatment for the elderly myeloma patient
Speaker invited

Session VII: Treatment V - Bones

Moderator: Roger Pearse, MD

5:10 pm

Basic science meets the bone
Suzanne Lentzsch, MD, PhD

5:30 pm

DEBATE: Bisphosphonates or monoclonal antibodies?

Bisphosphonates
James Berenson, MD

Monoclonal Antibodies
Noopur Raje, MD

6:10 pm

Adjourn


Friday, October 27, 2017

8:00 am

Welcome
Morton Coleman, MD

CHRONIC LYMPHOCYTIC LEUKEMIA SESSION

8:05 am

Introduction to CLL Session
Richard R. Furman, MD

Session VIII: Application of Novel Testing to the Clinic

Moderator: Richard R. Furman, MD

8:10 am

Pre-session audience survey

8:20 am

Introduction to Gebroe Family Lecture
Presenter: Morton Coleman, MD

8:30 am

Gebroe Family Lecture: Genomics 101: Prognostic Factors
Speaker invited

8:50 am

Risk Assessment in the Era of Novel Agents: What prognostic factors are clinically relevant?
Richard Furman, MD

9:10 am

Meaning of MRD: Is it clinically relevant?
Speaker invited

9:30 am

Panel discussion and post-session audience survey

9:45 am

Break

Session IX: Novel Small Molecules

Moderator: Kanti Rai, MD

10:05 am

Pre-session audience survey

10:10 am

Ibrutinib: real world experience
Anthony R. Mato, MD

10:30 am

Long-term updates on ibrutinib and idelalisib
Neil E. Kay, MD

10:50 am

Ibrutinib resistance: Is it predictable? What to do?
Speaker invited

11:10 am

Role of PI3K inhibitors in clinical practice: Uses and pitfalls
Jennifer Brown, MD

11:30 am

Other new molecules in the pipeline: PI3K inhibitors, SYK inhibitors, etc.
Speaker invited

11:50 am

Panel discussion and post-session audience survey

12:05 pm

Luncheon commercial programs

Session X: Special Topics in CLL I

Moderator: Moderator invited

1:35 pm

Pre-session audience survey

1:45 pm

Update on Venetoclax
Speaker invited

2:05 pm

Richter’s syndrome: What are the options?
Speaker invited

2:25 pm

Introduction to the Prince Family Lecture
Presenter: Morton Coleman, MD

2:35 pm

Prince Family Lecture: Clonal Evolution in CLL
Dan Landau, MD, PhD

2:55 pm

Panel Discussion and post session audience survey

3:10 pm

Break

Session XI: Special Lectures in CLL

Moderator: Moderator invited

3:30 pm

Update from the IWCLL 2017
Speaker invited

3:50 pm

Introduction to the Bruce Waterfall Memorial Debate in Waldenstrom macroglobulinemia (WM)
Presenter: Morton Coleman, MD

4:00 pm

DEBATE: What is the treatment choice for WM?

Bendamustine
Stephen M. Ansell, MD, PhD

Ibrutinib
Steven P. Treon, MD, PhD

4:30 pm

Panel discussion and questions

4:45 pm

Adjourn


Saturday, October 28, 2017

8:00 am

Welcome
Morton Coleman, MD

LYMPHOMA SESSION

8:05 am

Introduction to Lymphoma Session
John P. Leonard, MD

Session XII: Emerging Science

Moderator: Leandro Cerchietti, MD

8:10 am

Pre-session audience survey

8:20 am

What can canine lymphomas teach us about the treatment of human lymphomas?
Speaker invited

8:40 am

Will circulating tumor DNA have clinical utility in management of DLBCL and FL?
Speaker invited

9:00 am

What new targets may have clinical relevance soon in DLBCL?
Speaker invited

9:20 am

Panel discussion and post-session audience survey

9:35 am

Break

Session XIII: Treatment

Moderator: Peter Martin, MD

9:55 am

Pre-debate survey

10:05 am

DEBATE: How should an early progressor after bendamustine based treatment with FL be treated?

Autologous stem cell transplant
Speaker invited

Novel agents
Speaker invited

10:35 am

Post-debate audience survey and Pre-debate survey

10:45 am

DEBATE: What is the best treatment approach for relapsed mantle cell lymphoma?

Allogeneic stem cell transplant
Speaker invited

Novel agents
Peter Martin, MD

11:15 am

Post-debate survey

11:25 am

Key data from the International Conference on Malignant Lymphoma in Lugano, Switzerland
Speaker invited

Session XIV: Awards

Moderator: Morton Coleman, MD

11:45 am

Presentation of best lymphoma abstract

11:55 am

The SAAS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD, FACP, President & Director of Research for the SASS Foundation

Presentation: John Ultmann Award for contributions to lymphoma research
Presenter: David Maloney, MD

12:10 pm

CAR-T Therapy in Lymphoma and CLL
Speaker invited

12:30 pm

Discussion and post survey

12:45 pm

Luncheon

Session XV-A: Aggressive B- and T Cell Lymphoma

Parallel with Session XV-B: Indolent and Hodgkin lymphomas
Moderator: Sarah Rutherford, MD

2:15 pm

Pre-session audience survey

2:25 pm

What is the best initial therapy for peripheral T cell lymphoma?
Speaker invited

2:45 pm

Key novel agents for recurrent T cell lymphoma
Speaker invited

3:05 pm

What DLBCL patients should receive therapy different from R-CHOP?
John P. Leonard, MD

3:25 pm

Maintenance Therapy: Is it of value in Advanced DLBCL?
Thomas M. Haberman, MD

3:45 pm

Key novel agents for relapsed DLBCL
Anas Younes, MD

4:05 pm

Panel discussion and post-session audience survey

4:20 pm

What is the best therapy for primary mediastinal DLBCL
Speaker invited

4:40 pm

Adjourn

Session XV-B: Indolent and Hodgkin Lymphomas

Parallel with Session XV-A: Aggressive B- and T cell Lymphoma
Moderator: Morton Coleman, MD

2:15 pm

Pre-session audience survey

2:25 pm

Do any prognostic tools offer value in managing patients with Hodgkin lymphoma?
Speaker invited

2:45 pm

What is the future of checkpoint-inhibitor therapy in Hodgkin lymphoma?
Speaker invited

3:05 pm

How should we manage lymphocyte predominant Hodgkin lymphoma?
Speaker invited

3:25 pm

Pre-debate audience survey

3:35 pm

DEBATE: What is the best initial therapy for initial treatment of high tumor burden follicular lymphoma?

CHOP-based based therapy (and should it be with obinutuzumab or rituximab?)
Speaker invited

Bendamustine-based therapy (and should it be with obinutuzumab or rituximab?)
Speaker invited

4:05 pm

Marginal Zone Lymphoma
Morton Coleman, MD

4:25 pm

Panel discussion and post-session audience survey

4:40 pm

Adjourn

 

NURSING & ADVANCED PRACTITIONERS TRACK

Saturday, October 28, 2017

Session I: Updates in Hematology

Session Chair: Jeremy T. Heinerich

8:30 am

Welcome and introduction

8:45 am

Pre-activity Audience Survey

9:15 am

Managing CLL

9:45 am

Cytogenetics and Molecular Markers

10:15 am

Break

10:45 am

Multiple Myeloma today and tomorrow

11:15 am

Updates in Lymphoma

11:45 am

CAR-T use in Lymphoma, Myeloma and CLL

12:15 pm

New Agents within the last 2 years, a pharmacist lecture

12:45 pm

Lunch

Session II: Hematology Workshop

Session Chair: Speaker invited

2:15 pm

Introduction and pre-activity audience survey

2:30 pm

Bone Marrow Workshop

3:30 pm

Break

3:50 pm

Lumbar Puncture Workshop

4:50 pm

Final Remarks and post-activity audience survey

5:00 pm

Adjourn